Synvisc One 8mg/ml 1x6ml syringe


Synvisc is made from a hylan polymer, derived from chicken combs, which is chemically similar to the hyaluronic acid found in human synovial fluid. The treatment involves one to three injections into the knee joint, depending on the specific product used (e.g., Synvisc-One requires a single injection, while the traditional Synvisc regimen requires three injections given one week apart).



Synvisc, known generically as Hylan G-F 20, is a viscosupplementation injection used to relieve knee pain due to osteoarthritis for individuals who have failed to respond adequately to simple analgesics or physical therapy. Synvisc mimics the properties of synovial fluid, a naturally occurring substance in the joints that provides lubrication and cushioning. By improving the joint’s lubrication, Synvisc can reduce pain and improve joint mobility for some patients, potentially delaying surgery.

Additional information



● Synvisc is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond to conservative non-pharmacologic therapy and simple analgesics.

Administration Guidelines


● Synvisc-One: A single injection of 6mL directly into the knee joint.
● Traditional Synvisc: Three injections, each of 2mL, administered one week apart.

Method of Administration

● The injection should be administered by a healthcare professional trained in the technique, directly into the knee joint through sterile technique.

Dosage Form

● Synvisc is available as a viscoelastic, sterile, non-pyrogenic, elastoviscous fluid in pre-filled syringes for intra-articular injection.

Safety Preclusions

Pregnancy and Breastfeeding

● The safety of Synvisc in pregnant or breastfeeding women has not been established. It should be used only if needed and after a thorough risk/benefit analysis.

Long-term Use

● Long-term effects beyond six months are not well established. Treatment effectiveness and the need for repeat injections should be evaluated case-by-case.

Drug Interactions

● There are no known significant drug interactions with Synvisc. However, it is recommended to avoid using disinfectants containing quaternary ammonium salts for skin preparation as they may precipitate with hyaluronic acid.

Side Effects

● Patients may experience pain, swelling, heat, and/or redness in the injected knee following the injection. Joint stiffness and flu-like symptoms have also been reported.

Serious Side Effects

● Though rare, serious adverse events such as anaphylaxis, severe allergic reactions, and infection at the injection site are possible. Pseudosepsis (a severe inflammatory reaction) may also occur.


● Synvisc should be stored at 2°C to 25°C (36°F to 77°F). Do not freeze. Protect from light and excessive heat.

Special Precautions

● Synvisc should not be injected into the bloodstream or skin. It should not be used in patients with known hypersensitivity to hyaluronate preparations or those with infections or skin diseases in the area of the injection site.

● Patients should avoid strenuous activities or prolonged (more than one hour) weight-bearing activities such as running and tennis within 48 hours following the injection.


● There have been no reports of overdose with Synvisc. However, excessive injection volumes may lead to local adverse effects such as pain and swelling at the injection site. Treatment of overdose would be symptomatic and supportive.


There are no reviews yet.

Be the first to review “Synvisc One 8mg/ml 1x6ml syringe”

Your email address will not be published. Required fields are marked *